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Aim: Severe alpha1-antitrypsin (AAT) deficiency is one of the most common genetic
disorders in Caucasians. The aim of the present study was to assess an unbiased
frequencies of PI*S and PI*Z alleles using genotyping of a representative sample from the
general population of Poland.
Methods: A random sample of age- and gender-stratified residents, aged 20 years or older,
was drawn from the municipal directory of Krako´w, Poland. The two most common
deficiency alleles: PI*S and PI*Z were genotyped with qualitative real-time PCR using
degenerative dual-labeled allele-specific fluorescent probes.
Results: In the total population of 859 adult subjects (mean age: 49.5 years; range:
20–90), 28 heterozygotes MS, 18 heterozygotes MZ and one homozygote S were diagnosed.
The frequency of PI*S allele was 17.5 (95% CI: 11.6–23.9) per 1000; and that of PI*Z was
10.5 (95% CI: 5.8–15.7) per 1000. Therefore, the estimated prevalence of inherited severe
AAT deficiency (homozygotes Z) in Poland is 1/9110 (95% CI: 1/4057–1/29,727).
Conclusions: In the whole population of Poland comprising 38 millions, one may expect of
about 4189 (95% CI: 1284–9406) subjects with severe AAT deficiency. These numbers are
high enough to consider genetic testing being introduced into a common clinical practice.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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In 1962, a Swedish biochemist Carl-Bertil Laurell and a
clinician Sten Eriksson noticed that an absence of a protein
band in the alpha1 region of serum electrophoregram was
associated with pulmonary emphysema.1 Few years later, we
have described the first case of alpha1-antitrypsin (AAT)
deficiency in Poland.2 Severe AAT deficiency is one of the
most common Mendelian disorders in Caucasians. AAT is
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The prevalence of alpha1-antitrypsin in Poland 2521produced mainly in the liver. Its main function is to protect
the lung against proteolytic damage from neutrophil
elastase. The imbalance of protease–antiprotease ratio in
the lung tissue leads to the early-onset (below 45 years of
age) emphysema and chronic obstructive pulmonary disease
(COPD). Abnormal protein can polymerize in hepatocytes
causing liver disorders, such as prolonged neonatal jaun-
dice, cirrhosis and cancer. AAT deficiency is also associated
with panniculitis and Wegener’s granulomatosis.3
Over 120 different variants of AAT gene (SERPINA1) were
described, the most common causing clinically relevant
deficiency of the protein being: PI*S (Glu264-Val) and PI*Z
(Glu342-Lys).4 Unfortunately, the condition is often un-
diagnosed or misdiagnosed.5 Moreover, the current trends in
diagnosis are not improving.6 A reliable determination of the
allelic frequencies in the particular population is crucial to
estimate the numbers of subject at risk of complications
related to severe AAT deficiency and to organize the
national healthcare system for patients affected with this
condition. The aim of this study was to assess the unbiased
frequencies of PI*S and PI*Z using genetic tests and the
representative sample of Polish population.
Material and methods
Random sample of population
Krako´w with the community of approximately 741,000
inhabitants (578,000 adults) is the third largest city in
Poland. Clearance from the local authorities was obtained
and a random sample of 1500 age- and gender-stratified
individuals, aged 20 years or older, was drawn from the
Krako´w municipal directory using computerized method.
Taking into consideration a distance from the place of
screening visit and representativeness to city population,
the selection was restricted to the five (I, V, IX, XI and XIII) of
18 city districts. An invitation to participate included short
information on study aims and was sent by post. Addition-
ally, to improve the response rate, free of charge tests of
blood cell counts and serum lipids were offered and the
information in local media (TV, radio and newspapers) on
conducting survey and a request, pointed to all persons who
might receive the invitation letter to participate in, were
carried out. A second reminder was sent to non-responders
1 year after the first letter.
In order to increase the precision of allelic frequency
estimations, additional 309 samples of DNA were also
genotyped. They were collected in a previous study by us,
using random sampling, from inhabitants of Kazimierz,
another district of Krako´w.
Data and blood samples collection
A signed informed consent forms, including genetic testing,
were obtained from each participant in the study. The
survey was carried out in accordance with the Helsinki
Declaration and was approved by the Ethics Committee of
the Jagiellonian University in Krako´w. Blood samples were
collected, and general information on height, weight, COPD
and asthma symptoms, smoking expressed in ‘‘pack-years’’,
medical and family history were collected in a standardizedmanner by one investigator (MK). Laboratory tests were
carried out on site using a standard hospital facility. The
serum level of AATwas measured by a method of automated
immunonephelometry, using rabbit’s sera to highly purified
human AAT (Dade Behering, Magdeburg, Germany). Plasma
and serum samples were stored in 70 1C for further
investigations.
DNA isolation and AAT genotyping
DNA was isolated from the whole blood drawn on EDTA using
chaotropic lysis of white cells (DNAzol; Invitrogen, Carlsbad,
USA).7 DNA samples were then stored in 18 1C. Its
concentrations were in a range of 50–300 mg/ml. The two
most common AAT deficiency alleles PI*S and PI*Z, were
genotyped using a qualitative real-time PCR, which em-
ployed two sets of oligonucleotides: a pair of primers and a
pair of dual-labeled fluorescent probes. This technique,
called 50-nuclease assay, does not need post-amplification
processing and is relatively inexpensive, considering costs of
reagents and labor, and time-saving. The amplification and
fluorescence detection was carried out with iCycler iQ
(Bio-Rad, Hercules, USA) and genotypes were discriminated
using iCycler iQ Optical System Software v.3 (Bio-Rad). PCR
conditions and oligonucleotides’ sequences were as pub-
lished before.8 This assay was designed in our laboratory and
validated using reference test and external interlaboratory
quality control.
Statistical analysis
Statistical analysis was performed using Statistical Analysis
Software (v.9.1, SAS Institute). The allelic frequencies were
determined by the prevalence of heterozygotes and
calculated using bootstrap method with boot number of
100,000. The prevalence of the genotypes was calculated
from the Hardy–Weinberg formula. The data on the number
of individuals in Krako´w and Poland were obtained from the
Central Statistical Office (Warsaw, Poland). The 95% con-
fidence interval (CI) was estimated for each value.
Comparisons of the age of responders and non-responders
were performed with ANOVA; differences between median
AAT serum levels according to genotype, given with
interquartile range (IQR), were tested with Kruskal–Wallis
test. The w2 test was used for categorical variables. All
results were regarded as significant for the alpha error of
0.05 or less. A statistical Precision Factor Score (PFS) was
estimated according to method developed by Ferna´ndez-
Bustillo.9 In order to maintain a concordance to the
previously published values of other surveys, calculations
of PFS were performed with CI formulae using the original
spreadsheet kindly provided by Dr. Ignatio Blanco.
Results
Response rate
In the first step of enrollment, 1500 letters with invitation
were sent by post, 20 of them have been returned with
information: ‘‘addressee unknown’’ or ‘‘addressee dead’’.
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M.P. Kaczor et al.2522Five hundred and twenty three persons responded posi-
tively; the lowest response rate was noted in the youngest
age group. In the second step, the reminders were sent to
the subjects aged 20–39 years. Nevertheless, in this group
the response rate was only 6.3% and no further recruitment
was continued. Together, 550 randomly selected inhabitants
(248 men and 302 women) were recruited from a general
population of Krako´w for this study (Table 1). The response
rate was 36.7%. Significantly higher response was noted in
the older age groups, than in the work-active strata. The
mean age of responders was higher about 4.13 (95% CI:
2.23–6.02) years than in the group of non-responders
(po0.001).AAT genotyping
In the random sample of Krako´w population (n ¼ 550), 17
heterozygotes MS, 12 heterozygotes MZ and 1 homozygote S
were diagnosed. Therefore, the frequency of PI*S allele was
17.3 (95% CI: 10.0–25.5) per 1000; and PI*Z–10.9 (95% CI:
5.5–17.3) per 1000. Combining with the earlier collected
population of 309 randomly selected Kazimierz residents,
the overall results were: 28 heterozygotes MS, 18 hetero-
zygotes MZ and one homozygote S. These two population
samples did not differ significantly and were in the
Hardy–Weinberg equilibrium. In the total sample of 859Table 1 The characteristic of the population of Krako´w, rando
to age and sex.
Age (in years) Krako´w population Sele
Men (%) Women (%) Men
20–39 109,942 113,783 286
(19.0) (19.7) (19.
40–59 99,381 116,073 258
(17.2) (20.1) (17.
60 and above 54,853 84,151 142
(9.5) (14.6) (9.5
Combined 578,183 1500
Data of the Central Statistical Office on 31 December 2001.
Table 2 Expected numbers of AAT genotypes in Krako´w and in
Genotype Krako´w (n ¼ 757,762) Poland (n ¼
Number 95% confidence
interval
Number
MM (non-S, non-Z) 716,011 704,039–723,158 36,058,689
MS 25,725 16,945–35,384 1,295,522
MZ 15,435 8473–23,244 777,313
SZ 227 102–569 13,964
SS 231 102–433 11,636
ZZ 83 25–187 4189
Data of the Central Statistical Office on 30 June 2005.subjects, the estimated alleles’ frequencies per 1000 were
as follows: PI*M (non-S, non-Z)–972.1 (95% CI: 963.9–979.6);
PI*S–17.5 (95% CI: 11.6–23.9); and PI*Z–10.5 (95% CI:
5.8–15.7). Therefore, basing on allelic frequencies, the
prevalence of severe deficiency (homozygotes Z) was 1/9110
(95% CI: 1/4057–1/29,727), of the other deficiency combi-
nations: SS–1/3279 (95% CI: 1/1751–1/7432); SZ–1/2733
(95% CI: 1/1333–1/7432) and of carriers: MZ–1/49 (95% CI:
1/33–1/89); MS–1/29 (95% CI: 21–45). The total PI*S and PI*Z
prevalence was 1/18.
In the Polish population one may expect about 4189 (95%
CI: 1284–9406) subjects with severe AAT deficiency. Details
on the expected numbers of AAT genotypes in population of
Krako´w and Poland are given in Table 2.Serum level of AAT
In the group of subjects with wild genotype (non-S and non-
Z), the median level of AAT in serum (normal range:
0.9–2.0 g/l) was 1.23 g/l (IQR: 0.22); in MS heterozygo-
tes—1.08 g/l (IQR: 0.22) and in MZ heterozygotes—0.77 g/l
(IQR: 0.60). Differences in these levels between genotypes
were statistically significant (p ¼ 0.0001). The sensitivity of
AAT measurement in serum, for prediction of partial
deficiency, was 46.7% (95% CI: 28.3–65.7) and specifi-
city—99.0% (95% CI: 97.8–99.7).mly selected sample and participated group-strata according
cted Participated
(%) Women (%) Men (%) Women (%)
295 74 94
1) (19.7) (13.5) (17.1)
301 102 122
2) (20.1) (18.5) (22.2)
218 72 86
) (14.5) (13.1) (15.6)
550
Poland.
38,161,313) Prevalence
1/x
95% confidence
interval 1/x
95% confidence interval
35,455,798–36,418,624 – –
853,382–1,781,974 29 21–45
426,691–1,170,585 49 33–89
5135–28,639 2733 1333–7432
5135–21,798 3279 1751–7432
1284–9406 9110 4057–29,727
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Table 3 Published frequencies of AAT deficiency alleles in Polish population.
Study No. Method PFS Allele frequency (per 1000) Genotype diagnosed
S (95% CI) Z (95% CI) MS MZ SZ SS ZZ
Current study 859 Genotyping
(real-time PCR)
5.7 17.5 10.5 28 18 0 1 0
(11.6–23.9) (5.8–15.7)
Walter et al.12 423 IEF 4.2 16.5 14.2 14 12 0 0 0
(8.3–26.0) (7.1–22.5)
Kowalska et al.13,14 630 IEF 5.0 14.3 14.3 18 18 0 0 0
(7.9–21.4) (7.9–21.4)
Kowalska et al.15 741 IEF 3.9 9.4 6.7 12 10 0 1 0
(4.7–14.8) (2.7–11.5)
Combined (row 2–4) 1794 4.4 12.8 11.1 44 40 0 1 0
(9.2–16.7) (7.8–14.8)
Combined (all) 2653 4.8 14.5 10.9 72 58 0 2 0
(11.3–17.9) (8.3–13.8)
PFS—precision factor score; IEF—isoelectric focusing.
Weighted mean.
Figure 1 Geographic locations of surveys on frequencies (per
1000) of AAT deficiency alleles in Poland. Methods of sample
recruitment: Walter et al.12—195 unrelated residents city of
Ostro´w Wielkopolski and 228 Kashubes from Koscierzyna;
Kowalska et al.13,14—blood donors (n ¼ 181) and unrelated
inhabitants (n ¼ 450) city of Poznan´ and environs; Kowalska
et al.15—umbilical cord serum from 741 newborns collected in
five cities of Central Poland: Bydgoszcz, Warsaw, Poznan´, Piła,
Ciechano´w.
The prevalence of alpha1-antitrypsin in Poland 2523Discussion
In the random sample of general population comprising 859
subjects, we found the allelic frequency of PI*S–17.5 (95%
CI: 11.6–23.9) per 1000, and that of PI*Z–10.5 (95% CI:
5.8–15.7) per 1000. Our sample size exceeds the proposed
minimal value for such estimations.10 This is the first study
ascertaining the prevalence of AAT deficiency in Poland by
genotyping and a random sampling method. The results do
not differ significantly from the previously published
surveys, except the study by Opolska11 reporting seven-fold
lower frequency of Pi*Z. This discrepancy could easily be
explained by a low reliability of starch gel electrophoresis in
diagnosis of Z band due to diminished level of the protein.
Because of these limitations, the early data by Opolska were
removed from further analysis of AAT deficiency prevalence
in Poland. The detailed results of previous surveys,12–15
using more reliable method of isoelectric focusing (IEF), are
given in Table 3 and are illustrated by Figure 1 with
references to their geographical origin and sampling
methods.
Over the last few years, Blanco and de Serres published
systematic reviews and meta-analyses of AAT deficiency
phenotypes in Europe,9,16–18 and developed a precision
factor score for assessing the statistical quality of data, in
terms of precision (or imprecision) of each published survey.
Our study fulfills these inclusion criteria, with the precision
factor score of 5.7, which is the highest among the Polish
surveys (Table 3). Moreover, it seems to be the first study in
Europe on the prevalence of AAT deficiency in general
population using genotyping; and the second, after the work
by Blanco et al.,19 in which recruitment scheme warranted a
representative population sample.
In the latest meta-analysis on the prevalence of AAT
deficiency in Europe,18 Blanco and de Serres presented the
results for Poland: PI*S–15 (95% CI: 13–17) per 1000 and
PI*Z–4 (95% CI: 3–5) per 1000. As some of original studies
were available only in the Polish language, a bias in the
extraction of primary data could have occurred; e.g. twosurveys included20,21 referred to AAT phenotypes frequen-
cies in general population based on the results by Opolska.11
The most important problem in epidemiological studies is
representativeness of the results for the general popula-
tion.22–24 In our study, the response rate was moder-
ate—36.7%, which limits the validity of conclusions.
However, the allelic frequencies were determined mainly
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Figure 2 The frequencies (per 1000) of AAT deficiency alleles in Poland and other European countries. The data for the other
countries are from the meta-analyses by Blanco et al.18 A gradient distribution of AAT deficiency alleles declines across Europe from
the North to the South for PI*Z, and from the West to the South for PI*S. n/a—data not available.
M.P. Kaczor et al.2524by the prevalence of heterozygotes MZ and MS. In such
carriers for AAT deficiency, symptoms manifests only in case
of additional exposure to other risk factors.25–29 Therefore,
we avoided any influence of over-mortality within ZZ
homozygotes, potentially leading to underestimation of
PI*Z allele in the older age strata. Similarly, an over-
estimation of severe AAT deficiency due to higher response
rate of affected subjects was avoided. Based on all of the
Polish studies, a combined allelic frequency per 1000 is 14.5
(95% CI: 11.3–17.9) for PI*S and 10.9 (95% CI: 8.3–13.8) for
PI*Z (Table 3), which seems well fitting to a cross-European
gradient in frequency of this allele (Figure 2). Early
diagnosis of this genetic predisposition, with the appro-
priate medical follow-up and change of life style can
prevent or at least postpone an over AAT deficiency
complications.
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